PT - JOURNAL ARTICLE AU - Saadi, Nuru AU - Chi, Y-Ling AU - Ghosh, Srobana AU - Eggo, Rosalind M AU - McCarthy, Ciara AU - Quaife, Matthew AU - Dawa, Jeanette AU - Jit, Mark AU - Vassall, Anna TI - Models of COVID-19 vaccine prioritisation: a systematic literature search and narrative review AID - 10.1101/2021.06.21.21259104 DP - 2021 Jan 01 TA - medRxiv PG - 2021.06.21.21259104 4099 - http://medrxiv.org/content/early/2021/06/28/2021.06.21.21259104.short 4100 - http://medrxiv.org/content/early/2021/06/28/2021.06.21.21259104.full AB - Background How best to prioritise COVID-19 vaccination within and between countries has been a public health and an ethical challenge for decision-makers globally. We systematically reviewed epidemiological and economic modelling evidence on population priority groups to minimise COVID-19 mortality, transmission and morbidity outcomes.Methods We searched the National Institute of Health iSearch COVID-19 Portfolio (a database of peer-reviewed and pre-print articles), Econlit, the Centre for Economic Policy Research and the National Bureau of Economic Research for mathematical modelling studies evaluating the impact of prioritising COVID-19 vaccination to population target groups. We narratively synthesised the main study conclusions on prioritisation and the conditions under which the conclusions changed.Findings The search identified 1820 studies. 36 studies met the inclusion criteria and were narratively synthesised. 83% of studies described outcomes in high-income countries. We found that for countries seeking to minimise deaths, prioritising vaccination of senior adults was the optimal strategy and for countries seeking to minimise cases the young were prioritised. There were several exceptions to the main conclusion, notably reductions in deaths could be increased, if groups at high risk of both transmission and death could be further identified. Findings were also sensitive to the level of vaccine coverage.Interpretation The evidence supports WHO SAGE recommendations on COVID-19 vaccine prioritisation. There is however an evidence gap on optimal prioritisation for low- and middle-income countries, studies that included an economic evaluation, and studies that explore prioritisation strategies if the aim is to reduce overall health burden including morbidity.Competing Interest StatementThe authors have declared no competing interest.Funding StatementMJ was funded by the Bill & Melinda Gates Foundation (grant: INV-003174, INV-016832), National Institute for Health Research (grant: 16/137/109, NIHR200929, NIHR200908), and European Union's SC1- PHE-CORONAVIRUS-2020 programme (project EpiPose, grant: 101003688). YLC and SG were funded by the Bill & Melinda Gates Foundation (grant: OPP1202541 iDSIPlus). AV and NS were funded by the Bill & Melinda Gates Foundation (grant: OPP1202541 COVID IDSI). RE was funded by HDR UK (grant: MR/S003975/1), MRC (grant: MC_PC 19065), and NIHR (grant: NIHR200908). Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:NAAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe extracted data from the studies referred to in the manuscript is available in the supplementary material.